Irene Rossi

Irene Rossi is Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company where she leads a group focused on the development of new technologies for OINDP products comprising biologics and chemical entities. Having achieved a Master in Pharmaceutical Chemistry and Technology, Irene spent 6 years at the University of Parma working on formulation development of nasal and inhalation products, particularly focusing on particle engineering. She obtained her PhD in Drugs, Biomolecules and Health Products in 2019. To date, Irene has published six original papers, a patent application and has presented her work at over 20 international conferences.